Emergence of antimony (Sb) resistance has jeopardized the treatment of visceral leishmaniasis (VL) in various countries. Previous studies have considered the part played by leishmanial parasites in antimony resistance, but the involvement of host factors in the clinical scenario remained to be investigated. Here we show that unlike infection with Sb-sensitive 
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Emergence of antimony (Sb) resistance has jeopardized the treatment of visceral leishmaniasis (VL) in various countries. Previous studies have considered the part played by leishmanial parasites in antimony resistance, but the involvement of host factors in the clinical scenario remained to be investigated. Here we show that unlike infection with Sb-sensitive is otherwise lethal. The occurrence of a similar scenario in clinical cases is supported by the findings that unlike monocytes from SAG sensitive KA patients, monocytes from SAG unresponsive kala-azar (KA) patients overexpress P-gp and MRP1 and fail to accumulate Sb following in vitro SAG treatment unless pretreated with inhibitors of ABC transporters. Thus, the expression status of MRP1 and P-gp in blood monocytes may be used as a diagnostic marker for Sb resistance and the treatment strategy can be designed accordingly. Our results also indicate that lovastatin, which can inhibit both P-gp and MRP1 might be beneficial to revert Sb resistance in leishmaniasis as well as drug resistance in other clinical situations including cancer.
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Introduction:
Emergence of antimony resistant visceral leishmaniasis (VL) in various parts of the world (1, 8, 17, 49) has severely compromised the disease control. Among alternative drugs, pentamidine is toxic, amphotericin B is both expensive and toxic with reported cases of resistance (8, 49) and usage of oral miltefosine is limited by its cost, contraindications and emerging resistance (1, 8, 25, 42) . Therefore, understanding of the mode of resistance and identification of cost-effective therapeutic combinations has become major issues. amastigotes from field isolates of Sb R -LD (10, 52) . Although sodium antimony gluconate (SAG) kills leishmanial amastigotes directly at higher doses in vitro as reported previously (53) , a much lower dose is required for killing the parasite within macrophages (Mφ) (26).
Furthermore, SAG fails to act in immunocompromised hosts, such as patients who are suffering from AIDS or receiving immunosuppressive agents (19, 37) and nude (40) and severe combined immunodeficient (SCID) mice (16) . Several studies have shown that endogenous interleukin-2 (IL-2) (39), IL-4 (2, 41), and IL-12 (38) influence the effectiveness of chemotherapy with pentavalent antimony. Together, these findings are inclined to indicate the requirement of a somewhat functional immune system for SAG action. We also demonstrated earlier that SAG induces the Mφ to produce leishmanicidal molecules like nitric 
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oxide (NO) and reactive oxygen species (ROS) leading to elimination of intracellular LD (34) . Thus SAG may act both directly as well as through activation of host's macrophage. (46) and two SAG resistant (Sb R ) strains, GE1F8R (raised in vivo in hamsters) (4), and K39
(isolated from SAG unresponsive patient) (47) were used. Amastigotes obtained from the spleen of infected hamsters were cultured at 22 0 C to obtain promastigotes (6).
Animals:
BALB/c mice, originally obtained from Jackson Laboratories, (Bar Harbor, ME, USA), Golden Syrian hamsters (Mesocrecetus auratus) obtained originally from National Institute of Nutrition, Hyderabad, India, both reared in the institute animal facilities, were used for experimental purposes with prior approval of the animal ethics committee.
Cell lines and cell culture:
Four different cell lines were used in this investigation and they are Peritoneal macrophages (Mφ) were obtained from BALB/c mice as described previously (34) and used for further experimentations. Splenic Mφs were isolated from BALB/c mice infected for 2 months with SAG sensitive (Sb S ) or SAG resistant (Sb R ) LD as described previously (46) .
LD infection (in vitro and in vivo) and determination of parasite burden
Mφs were infected with either Sb S or Sb R LD promastigotes as described previously (34) . Intracellular LD parasite number of infected Mφs was enumerated in Giemsa-staining as described elsewhere (34).
4-6 weeks old BALB/c mice were infected with 1x10 7 promastigotes (AG83 or GE1F8R or K39) / 0.1mL / animal via intra-cardiac (ic) route (46) and 2-month infected mice were used for experimental purpose.
Four weeks old golden hamsters were infected with K39 (2x10 7 promastigotes/ 0.1 mL/ animal) or GE1F8R (5 x10 6 amastigotes/ 0.1 mL/animal) ic (day 0) (4). For subsequent experiments 30 day GE1F8R infected hamsters and 60 day K39 infected hamsters respectively were used because at these time points two groups of hamsters showed almost equal parasite burden in spleen and liver. The parasite burden was determined by limiting dilution of tissue samples (4).
Peripheral blood sample of patients:
Excesses blood drawn for routine examinations of confirmed kala-azar (KA) patients, either confirmed unresponsive (patients reported to the clinic with KA with in two months of receiving full course of SAG) or sensitive to SAG (KA patients showed improvement of negative. Parasite burden in splenic aspirates was determined using the method described by
Chuley and Bryceson (7) . A brief profile of patients is presented in Tables 1 and 2 .
Monocytes from peripheral blood mononuclear cells from KA patients were isolated by adherence on plastic petridish and used for further experimentation.
Treatments:
At 22 h post infection the Mφs (1X10 6 ) were treated with SAG (10 µg/ ml in terms of Sb content) (34 
Measurement of reactive oxygen species (ROS):
The level of ROS (includes superoxide, hydrogen peroxide and other reactive oxygen intermediates) was monitored using the cell permeable nonpolar H 2 O 2 sensitive probe DCFDA as described before (34) .
Measurement of nitric oxide (NO):
NO generation in response to SAG treatment was monitored by Griess reaction as described previously (34) .
Quantification of intracellular antimony:
Total intracellular antimony (Sb) contents were measured in SAG (10 µg/ml) treated cells by electrothermal atomic absorption spectroscopy as described previously (44) with minor modifications.
Detection of expression of MRP1 and P-gp:
The levels of expression of MRP1 and P-gp in Mφ or peripheral blood monocytes of the patients were determined by immuno-staining followed by flowcytometry (Becton Dickson) and/or confocal microscopy (LSM 510; Carl Zeiss, Jena, Germany) as described 
Doxorubicin retention assay
Doxorubicin retention assay was performed using EAC/Dox cell following the method described elsewhere (54) 
Statistical analysis:
Each experiment was performed 3 to 5 times and results are expressed as mean ± SE.
Student's t-test for significance was performed and p<0.05 was considered significant.
ANOVA with a post test correction for multiple groups was used for statistical analysis of the data and p<0.05 was considered significant. Representative data of flow-cytometry and fluorescence microscopy of at least three independent experiments are presented. 
Expression of MRP1 and P-gp in macrophages following infection
Over-expression of ABC transporters like P-gp or MRP1 causes multiple drug resistance (MDR) in different diseases (5) 
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observation was further confirmed by confocal microscopy of GE1F8R-Mφ, in which varying degrees of P-gp and MRP1 colocalization was observed (Fig 2B) .
In order to confirm these observations in an in vivo experimental setting, the expression level of MRP1 and P-gp was tested in splenic Mφs from BALB/c mice infected with either Sb S LD or Sb R -LD. Splenic Mφ population derived from Sb R -LD infected mice
showed remarkable increase in P-gp single positive (Fig. 2C ) and MRP1-P-gp double positive cells (Fig. 2C ) compared to splenic Mφ from Sb S LD infected mice.
Involvement of ABC transporters in Sb clearance
To determine whether higher expression of P-gp and MRP1 are indeed involved in the non-retention of Sb, four cell lines, viz., MRP1 over-expressing EAC/Dox (32, 33), P-gp over-expressing CEM-ADR5000 (14), and their respective parental dox-sensitive counterparts EAC/S and CCRF/CEM were treated with SAG for 6 h and the total intracellular Sb content was measured. Unlike their parental counterparts, both EAC/Dox and CEM/ADR5000 failed to retain Sb (Fig. 3A, B) . Furthermore, EAC/Dox retained Sb following SAG treatment in presence of the MRP1 inhibitor probenecid (18, 21) but not verapamil (Fig. 3A) while CEM/ADR5000 retained Sb in presence of the P-gp inhibitory isoform of verapamil (27, 50, 51) but not probenecid (Fig. 3B) . Thus drug sensitivity correlates with ABC transporter expression and strongly suggests a selective involvement of P-gp and MRP1 in Sb clearance from EAC/Dox and CEM/ADR5000 lines repectively. Interestingly, both EAC/Dox and CEM/ADR5000 cell lines retained Sb when treated with SAG in presence lovastatin (Fig. 3A,   B ). This indicates that in addition to its previously reported P-gp inhibitory effect (54), lovastatin may also inhibit MRP1. To confirm this we performed dox retention assay in EAC/Dox in the presence of lovastatin. Pretreatment of EAC/Dox with lovastatin for 60 min before loading with dox resulted in a dose dependent increase in the retention of dox, reaching a plateau at a 10 µM lovastatin dose (Fig. 3C ). Confocal microscopy further confirmed that (Fig. 4B ). This confirms that inhibition of both P-gp and MRP1 are necessary to prevent Sb efflux and promote SAG mediated parasite clearance.
Inhibitors of ABC transporters as resistance modifying agents
Since experimental VL in hamsters closely mimic KA in human, inhibitors of P-gp and MRP1 as potential RMA were evaluated in hamsters infected with Sb R LD. GE1F8R
infected or K39 infected hamsters were divided into six groups (I-VI) and received treatments as described in materials and method. GE1F8R-infected hamsters showed hardly any reduction of parasite burden upon SAG treatment (Fig. 5A ) whereas similar treatment of K39- 
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infected hamsters caused ~15% reduction in parasite burdens in spleen, confirming that these two LD parasite strains are indeed SAG resistant in an in vivo setting. Treatment with probenecid (Group III) led to SAG mediated reduction in spleen and liver parasite burden respectively by ~27% and ~35% in GE1F8R-infected hamsters and by 33% and 23% in K39-infected hamsters as compared to the untreated infected group (Group I). Interestingly, group IV hamsters, which received verapamil plus SAG, showed significantly more reduction of parasite burden in both spleen and liver as compared to hamsters treated with SAG only (p<0.001). Oral treatment with a combination of probenecid and verapamil (Group V) or with lovastatin (Group VI) prior to SAG treatment showed reductions of >90% (~10 17 fold) and >95% (~10 18 fold) respectively in both hepatic and splenic parasite burdens ( Fig 5A) and offered sterile protection in spleen and liver in the majority of GE1F8R-infected and K39-infected hamsters (Table 3 ).
The survival rate was studied in each experimental group till 240 days (Fig 5B) . Data from group I was similar to group II and is not shown. All GE1F8R-infected and K39-infected hamsters belonging to groups I and II died by 90 days and 120 days respectively after infection. Survival of both GE1F8R-infected and K39-infected hamsters could be improved only to some extent with either probenecid or verapamil treatment prior to each SAG treatment while all animals belonging to group V (probenecid + verapamil + SAG) and group VI (lovastatin + SAG) survived till termination of experiment (240 days) ( 
GE1F8R infection and 120 days post infection in case of K39 infection (data not shown).
Interestingly, ~60% of the only lovastatin treated animals survived till 75 days post infection in case of GE1F8R infection and 105 days post infection in case of K39 infection (Fig. 5 ),
indicating that only lovastatin treatment slows down the progression of the disease.
Expression of ABC transporters in monocytes of Kala-Azar patients
In order to evaluate the role of ABC transporters in Kala-azar (KA) patients, we although the level of expression of MRP1 and P-gp varied from patient to patient (Fig. 6 ).
When the monocytes from these patients were treated with SAG in vitro, the cells from 
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To examine the Sb-sensitivity, parasites were isolated from splenic aspirates of fresh (i.e., untreated) KA patients, propagated in culture and were used to infect Mφ from normal BALB/c mice. More than 90% intracellular parasites derived from KA patients belonging to Sb sensitive area were eliminated by 10 µg/mL SAG in vitro whereas similar dose of SAG eliminated less than 50% of the intracellular parasites isolated from KA patients belonging to Sb-resistant areas (Fig 7A) . Moreover, in contrast to parasites derived from KA patient from Sb-sensitive areas, infection with parasites from Sb-unresponsive areas could upregulate of Pgp and MRP1 of Mφ derived from BALB/c mice (Fig. 7B) .
Role of parasite antigen in upregulation of expression of host's ABC transporters
Since peripheral blood monocytes of the Sb R -KA patients do not harbor demonstrable parasites at the active stage of the disease but still possess upregulated P-gp and MRP1 expression, it is likely that soluble and circulating parasite antigens may cause upregulation of expression of these transporters. To test this hypothesis we incubated overnight uninfected macrophages from normal BALB/c mice with crude antigens from sonicated Sb R -LD strains (GE1F8R or K39). We observed that Sb R -LD parasite antigens could induce upregulation of MRP1 and P-gp in uninfected Mφ (Fig.8A) . Moreover, incubation of uninfected Mφ with Table 1 .
(C)
Expression status of MRP1 and P-gp, and Sb retention ability of monocytes of twenty fresh KA patients, out of which ten came from SAG sensitive zone and the rest from SAG resistant zone. Identical studies were performed as done with Sb R -KA and Sb R -KA monocytes. Details of the patients are described in Table 2 . Table 2 is given). After 22h >85% cells were infected (1288±167 Sb R parasites/100 Mφ and 1056±124 Sb S parasites/100 Mφ).
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